Jana Kotašková, Ph.D.

Publications that are part of the Web of Science database, possibly also other publications chosen by authors.

2021

• Navrkalova, V; Plevova, K; Hynst, J; Pal, K; Mareckova, A; Reigl, T; Jelinkova, H; Vrzatova, Z; Starska, K; Pavlova, S; Panovska, A; Janikova, A; Doubek, M; Kotaskova, J; Pospisilova, S, 2021: LYmphoid NeXt-Generation Sequencing (LYNX) Panel A Comprehensive Capture-Based Sequencing Tool for the Analysis of Prognostic and Predictive Markers in Lymphoid Malignancies. JOURNAL OF MOLECULAR DIAGNOSTICS 23(8), p. 959 - 974, doi: 10.1016/j.jmoldx.2021.05.007

2020

• Condoluci, A; di Bergamo, LT; Langerbeins, P; Hoechstetter, MA; Herling, CD; De Paoli, L; Delgado, J; Rabe, KG; Gentile, M; Doubek, M; Mauro, FR; Chiodin, G; Mattsson, M; Bahlo, J; Cutrona, G; Kotaskova, J; Deambrogi, C; Smedby, KE; Spina, V; Bruscaggin, A; Wu, W; Moia, R; Bianchi, E; Gerber, B; Zucca, E; Gillessen, S; Ghielmini, M; Cavalli, F; Stussi, G; Hess, MA; Baumann, TS; Neri, A; Ferrarini, M; Rosenquist, R; Forconi, F; Foa, R; Pospisilova, S; Morabito, F; Stilgenbauer, S; Dohner, H; Parikh, SA; Wierda, WG; Montserrat, E; Gaidano, G; Hallek, M; Rossi, D, 2020: International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. BLOOD 135(21), p. 1859 - 1869, doi: 10.1182/blood.2019003453
• Malcikova, J; Pavlova, S; Vonkova, B; Kotaskova, J; Radova, L; Plevova, K; Zenatova, M; Hynst, J; Dvorackova, B; Panovska, A; Brychtova, Y; Tichy, B; Navrkalova, V; Pal, K; Mayer, J; Doubek, M; Pospisilova, S, 2020: Minor-clone TP53 mutations in CLL patients entering first-line treatment: clonal evolution and clinical impact. LEUKEMIA & LYMPHOMA 61, p. 222 - 224

2019

• Hernandez-Sanchez, M; Kotaskova, J; Rodriguez, AE; Radova, L; Tamborero, D; Abaigar, M; Plevova, K; Benito, R; Tom, N; Quijada-Alamo, M; Bikos, V; Martin, AA; Pal, K; de Coca, AG; Doubek, M; Lopez-Bigas, N; Hernandez-Rivas, JM; Pospisilova, S, 2019: CLL cells cumulate genetic aberrations prior to the first therapy even in outwardly inactive disease phase. LEUKEMIA 33(2), p. 518 - 522, doi: 10.1038/s41375-018-0255-1
• Baliakas, P; Moysiadis, T; Hadzidimitriou, A; Xochelli, A; Jeromin, S; Agathangelidis, A; Mattsson, M; Sutton, LA; Minga, E; Scarfo, L; Rossi, D; Davis, Z; Villamor, N; Parker, H; Kotaskova, J; Stalika, E; Plevova, K; Mansouri, L; Cortese, D; Navarro, A; Delgado, J; Larrayoz, M; Young, E; Anagnostopoulos, A; Smedby, KE; Juliusson, G; Sheehy, O; Catherwood, M; Strefford, JC; Stavroyianni, N; Belessi, C; Pospisilova, S; Oscier, D; Gaidano, G; Campo, E; Haferlach, C; Ghia, P; Rosenquist, R; Stamatopoulos, K, 2019: Tailored approaches grounded on immunogenetic features for refined prognostication in chronic lymphocytic leukemia. HAEMATOLOGICA 104(2), p. 360 - 369, doi: 10.3324/haematol.2018.195032
• Bereshchenko, O; Lo Re, O; Nikulenkov, F; Flamini, S; Kotaskova, J; Mazza, T; Le Pannerer, MM; Buschbeck, M; Giallongo, C; Palumbo, G; Li Volti, G; Pazienza, V; Cervinek, L; Riccardi, C; Krejci, L; Pospisilova, S; Stewart, AF; Vinciguerra, M, 2019: Deficiency and haploinsufficiency of histone macroH2A1.1 in mice recapitulate hematopoietic defects of human myelodysplastic syndrome. CLINICAL EPIGENETICS 11(1), doi: 10.1186/s13148-019-0724-z
• Condoluci, A; di Bergamo, LT; Langerbeins, P; Hoechstetter, M; Herling, C; De Paoli, L; Delgado, J; Rabe, KG; Gentile, M; Doubek, M; Mauro, FR; Chiodin, G; Mattsson, M; Bahlo, J; Cutrona, G; Kotaskova, J; Deambrogi, C; Spina, V; Bruscaggin, A; Moia, R; Bianchi, E; Gerber, B; Zucca, E; Ghielmini, M; Cavalli, F; Stussi, G; Neri, A; Ferrarini, M; Rosenquist, R; Forconi, F; Foa, R; Pospisilova, S; Morabito, F; Parikh, SA; Wierda, WG; Montserrat, E; Gaidano, G; Hallek, M; Rossi, D, 2019: International Prognostic Score (IPS-A) for Patients with Early Stage Chronic Lymphocytic Leukemia. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 19, p. S278 - S278, doi: 10.1016/j.clml.2019.07.212
• Jarosov?, M; Plevov?, K; Kotaskov?, J; Doubek, M; Posp?silov?, S, 2019: The importance of complex karyotype in prognostication and treatment of chronic lymphocytic leukemia (CLL): a comprehensive review of the literature. LEUKEMIA & LYMPHOMA 60(10), p. 2348 - 2355, doi: 10.1080/10428194.2019.1576038

2018

• Brazdilova, K; Plevova, K; Francova, HS; Kockova, H; Borsky, M; Bikos, V; Malcikova, J; Oltova, A; Kotaskova, J; Tichy, B; Brychtova, Y; Mayer, J; Doubek, M; Pospisilova, S, 2018: Multiple productive IGH rearrangements denote oligoclonality even in immunophenotypically monoclonal CLL. LEUKEMIA 32(1), p. 234 - 236, doi: 10.1038/leu.2017.274

2017

• Delgado, J; Doubek, M; Baumann, T; Kotaskova, J; Molica, S; Mozas, P; Rivas-Delgado, A.; Morabito, F; Pospisilova, S; Montserrat, E, 2017: Chronic lymphocytic leukemia: A prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytogenetics) separates patients with different outcome and simplifies the CLL-IPI. AMERICAN JOURNAL OF HEMATOLOGY , doi: 10.1002/ajh.24660
• Plevova, K; Malcikova, J; Pavlova, S; Kotaskova, J; Poppova, L; Smardova, J; Diviskova, E; Durechova, K; Oltova, A; Brychtova, Y; Panovska, A; Doubek, M; Pospisilova, S, 2017: BIALLELIC TP53 GENE MUTATIONS DUE TO COPY-NEUTRAL LOSS OF HETEROZYGOSITY AND MONOALLELIC MUTATIONS IN ABSENCE OF 17P DELETION OCCUR IN CLL WITH COMPARABLE FREQUENCY. HAEMATOLOGICA 102, p. 65 - 66
• Baliakas, P; Jeromin, S; Iskas, M; Puiggros, A; Plevova, K; Xochelli, A; Delgado, J; Kotaskova, J; Stalika, E; Abrisqueta, P; Durechova, K; Papaioannou, G; Collado, R; Doubek, M; Calasanz, MJ; Ruiz-Xiville, N; Moreno, C; Leeksma, AC; Anagnostopoulos, A; Ghia, P; Stavroyianni, N; Kater, AP; Espinet, B; Pospisilova, S; Athanasiadou, A; Stamatopoulos, K; Haferlach, C, 2017: CYTOGENETIC COMPLEXITY IN CHRONIC LYMPHOCYTIC LEUKEMIA: DEFINITIONS, ASSOCIATIONS WITH OTHER BIOMARKERS AND CLINICAL IMPACT; A RETROSPECTIVE STUDY ON BEHALF OF ERIC. HAEMATOLOGICA 102, p. 170 - 170
• Kotaskova, J; Pavlova, S; Plevova, K; Malcikova, J; Stehlikova, O; Poppova, L; Kockova, H; Doubek, M; Bryja, V; Pospisilova, S, 2017: TREATMENT WITH BCR INHIBITORS INCREASES ROR1 EXPRESSION IN CLL CELLS. HAEMATOLOGICA 102, p. 414 - 414
• Baliakas, P; Jeronim, S; Iskas, M; Puiggros, A; Plevova, K; Xochelli, A; Delgado, J; Kotaskova, J; Stalika, E; Costa, PA; Durechova, K; Papaioannou, G; Collado, R; Doubek, M; Calasanz, MJ; Ruiz-Xiville, N; Moreno, C; Anagnostopoulos, A; Stavroyianni, N; Kater, A; Espinet, B; Pospisilova, S; Athanasiadou, A; Stamatopoulos, K; Haferlach, C, 2017: Cytogenetic complexity in chronic lymphocytic leukemia: definitions, associations with other bio-markers and clinical impact. LEUKEMIA & LYMPHOMA 58, p. 65 - 66
• Baumann, T; Doubek, M; Kotaskova, J; Molica, S; Mozas, P; Rivas-Delgado, A; Morabito, F; Pospisilova, S; Delgado, J; Montserrat, E, 2017: The Barcelona-Brno Biomarkers-Only (IGHV mutational status and FISH cytogenetics) prognostic model for chronic lymphocytic leukemia. LEUKEMIA & LYMPHOMA 58, p. 147 - 149
• Malcikova, J; Kotaskova, J; Tom, N; Pal, K; Panovska, A; Brychtova, Y; Doubek, M; Pavlova, S; Pospisilova, S, 2017: Tracking low-burden TP53-mutated subclones during CLL treatment and remission using ROR1 separation. LEUKEMIA & LYMPHOMA 58, p. 162 - 163
• Vavrova, E; Kantorova, B; Vonkova, B; Kabathova, J; Skuhrova-Francova, H; Diviskova, E; Letocha, O; Kotaskova, J; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2017: Fragment analysis represents a suitable approach for the detection of hotspot c.7541_7542delCT NOTCH1 mutation in chronic lymphocytic leukemia. LEUKEMIA RESEARCH 60, p. 145 - 150, doi: 10.1016/j.leukres.2017.08.001

2016

• Poppova, L; Janovska, P; Plevova, K; Radova, L; Plesingerova, H; Borsky, M; Kotaskova, J; Kantorova, B; Hlozkova, M; Figulova, J; Brychtova, Y; Machalova, M; Urik, M; Doubek, M; Kozubik, A; Pospisilova, S; Pavlova, S; Bryja, V, 2016: Decreased WNT3 expression in chronic lymphocytic leukaemia is a hallmark of disease progression and identifies patients with worse prognosis in the subgroup with mutated IGHV. BRITISH JOURNAL OF HAEMATOLOGY 175(5), p. 851 - 859, doi: 10.1111/bjh.14312
• Hernandez-Sanchez, M; Radova, L; Kotaskova, J; Tamborero, D; Rodriguez, AE; Plevova, K; Abaigar, M; Bikos, V; Benito, R; Takacova, S; Quijada, M; Martin, AA; Alcoceba, M; de Coca, AG; Doubek, M; Gonzalez, M; Lopez-Bigas, N; Pospisilova, S; Hernandez-Rivas, JM, 2016: Analysis of Clonal Evolution in Chronic Lymphocytic Leukemia from Inactive to Symptomatic Disease Prior Treatment Using Whole-Exome Sequencing. BLOOD 128(22)
• Baliakas, P; Puiggros, A; Xochelli, A; Sutton, LA; Nguyen-Khac, F; Gardiner, A; Plevova, K; Minga, E; Hadzidimitriou, A; Walewska, R; McCarthy, H; Ortega, M; Collado, R; Gonzalez, T; Granada, I; Luno, E; Kotaskova, J; Moysiadis, T; Davis, Z; Stavroyianni, N; Anagnostopoulos, A; Strefford, JC; Pospisilova, S; Davi, F; Athanasiadou, A; Rosenquist, R; Oscier, D; Espinet, B; Stamatopoulos, K, 2016: Additional trisomies amongst patients with chronic lymphocytic leukemia carrying trisomy 12: the accompanying chromosome makes a difference. HAEMATOLOGICA 101(7), p. 299 - 302, doi: 10.3324/haematol.2015.140202
• Poppova, L; Janovska, P; Plevova, K; Radova, L; Plesingerova, H; Borsky, M; Kotaskova, J; Kantorova, B; Hlozkova, M; Figulova, J; Brychtova, Y; Doubek, M; Kozubik, A; Pospisilova, S; Pavlova, S; Bryja, V, 2016: DECREASED EXPRESSION OF WNT3, A CANONICAL WNT PATHWAY LIGAND, IS FREQUENT IN CHRONIC LYMPHOCYTIC LEUKEMIA PROGRESSION AND IDENTIFIES PATIENTS WITH SHORT TREATMENT-FREE SURVIVAL IN MUTATED IGHV SUBSET. HAEMATOLOGICA 101, p. 423 - 424
• Kotaskova, J; Pavlova, S; Greif, I; Stehlikova, O; Plevova, K; Janovska, P; Brychtova, Y; Doubek, M; Pospisilova, S; Bryja, V, 2016: ROR1-based immunomagnetic protocol allows efficient separation of CLL and healthy B cells. BRITISH JOURNAL OF HAEMATOLOGY 175(2), p. 339 - 342, doi: 10.1111/bjh.13848

2015

• Baliakas, P; Hadzidimitriou, A; Mattsson, M; Xochelli, A; Sutton, LA; Minga, E; Scarfo, L; Rossi, D; Davis, Z; Agathangelidis, A; Villamor, N; Parker, H; Kotaskova, J; Stalika, E; Plevova, K; Mansouri, L; Cortese, D; Lopez, AN; Delgado, J; Larrayoz, M; Anagnostopoulos, A; Belessi, C; Smedby, KE; Juliusson, G; Strefford, JC; Pospisilova, S; Oscier, D; Gaidano, G; Campo, E; Ghia, P; Rosenquist, R; Stamatopoulos, K, 2015: REFINING PROGNOSIS OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH SOMATICALLY HYPERMUTATED B-CELL RECEPTORS: A NOVEL PROGNOSTIC INDEX ON BEHALF OF THE EUROPEAN RESEARCH INITIATIVE ON CLL (ERIC). HAEMATOLOGICA 100, p. 52 - 52
• Plesingerova, H; Janovska, P; Poppova, L; Shaik, A; Jurcickova, Z; Libra, A; Plevova, K; Machac, J; Slapak, I; Pavlova, S; Ovesna, P; Kotaskova, J; Doubek, M; Pospisilova, S; Bryja, V, 2015: UPREGULATED COBLL1 IN CHRONIC LYMPHOCYTIC LEUKAEMIA (CLL) PATIENTS WITH UNMUTATED IGHV IDENTIFIES A COHORT WITH INFERIOR PROGNOSIS. HAEMATOLOGICA 100, p. 50 - 50
• Baliakas, P; Puiggros, A; Xochelli, A; Sutton, LA; Nguyen-Khac, F; Gardiner, A; Plevova, K; Ortega, M; Collado, R; Gonzalez, T; Granada, I; Luno, E; Kotaskova, J; Davis, Z; Anagnostopoulos, A; Strefford, J; Pospisilova, S; Davi, F; Athanasiadou, A; Rosenquist, R; Oscier, D; Sola, BE; Stamatopoulos, K, 2015: ADDITIONAL TRISOMIES AMONGST PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA CARRYING TRISOMY 12: THE PARTNER CHROMOSOME MAKES A DIFFERENCE. HAEMATOLOGICA 100, p. 224 - 224
• Kotaskova, J; Malcikova, J; Diviskova, E; Pavlova, S; Mejstrikova, S; Vranova, V; Plevova, K; Plesingerova, H; Doubek, M; Mayer, J; Pospisilova, S, 2015: 13Q DELETION IS PREDOMINANT CYTOGENETIC ABERRATION NEWLY AQUIRED DURING CHRONIC LYMPHOCYTIC LEUKEMIA COURSE IRRESPECTIVE OF DISEASE ACTIVITY AND TREATMENT STATUS. HAEMATOLOGICA 100, p. 417 - 418
• Kantorova, B; Malcikova, J; Smardova, J; Pavlova, S; Trbusek, M; Tom, N; Plevova, K; Tichy, B; Truong, S; Diviskova, E; Kotaskova, J; Oltova, A; Patten, N; Brychtova, Y; Doubek, M; Mayer, J; Pospisilova, S, 2015: TP53 mutation analysis in chronic lymphocytic leukemia: comparison of different detection methods. TUMOR BIOLOGY 36(5), p. 3371 - 3380, doi: 10.1007/s13277-014-2971-0

• Expression and function of activation-induced cytidine deaminase splice variants in normal B cell physiology and chronic lymphocytic leukemia (3SGA5792), Jihomoravský kraj, 2013 - 2016
• Functional and structural changes of microRNAs in lymphoproliferative malignancies and their impact on prognosis and prediction of therapy response (NT11218), Ministry of Health - Ministry of Health´s Departmental Research and Development Programme III (2010-2015), 2010 - 2015
• NGS-PTL - Next Generation Sequencing platform for targeted Personalized Therapy of Leukemia (306242), Evropská unie, 2012 - 2015
• SuPReMMe - Podpora profesního růstu a mezinárodní integrace výzkumných týmů v oblasti molekulární medicíny (CZ.1.07/2.3.00/20.0045), Ministerstvo školství, mládeže a tělovýchovy ČR, 2011 - 2014
• Real-time PCR soupravy pro diagnostiku v onkologii (FR-TI2/254), Ministerstvo průmyslu a obchodu ČR, 2010 - 2013
• Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies (MSM0021622430), Ministerstvo školství, mládeže a tělovýchovy ČR, 2007 - 2013
• Involvement of nuclear HMGB proteins in sensitizing of human cells to anticancer drugs inhibiting DNA topoizomerases (GAP301/10/0590), Czech Science Foundation - Standard Grants, 2010 - 2012
• Analysis of changes in genome and its expression in chronic lymphocytic leukemia patients during the disease development (NS10439), Ministry of Health - Departmental Programme of Research and Development (2008-2011), 2009 - 2011